Hermetica Superfood Encyclopedia
The Short Answer
Visnagin is a furochromone compound derived from the plant Ammi visnaga that exerts organ-protective effects primarily through inhibition of pro-inflammatory cytokines and modulation of oxidative stress pathways. Preclinical research highlights its potential in protecting the kidneys and heart from chemotherapy-induced damage without compromising anticancer efficacy.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordvisnagin benefits
Synergy Pairings3
Visnagin — botanical close-up
Health Benefits
Origin & History
Natural habitat
Visnagin is a furanochromone compound extracted from the flowers and seeds of Ammi visnaga L. (Khella), a Mediterranean plant in the Apiaceae family. It is typically obtained through aqueous extraction methods from plant material, with extracts often standardized to visnagin content.
“Ammi visnaga, the source of visnagin, has been used in Middle Eastern and North African traditional medicine, particularly in Unani and Arabic systems. Traditional applications included treatment of urinary disorders, kidney stones, and as a diuretic and spasmolytic agent.”Traditional Medicine
Scientific Research
No human clinical trials or RCTs were identified for visnagin; all evidence comes from preclinical animal and in vitro studies. Key studies include rat models of testicular injury (n=28, PMID: 37916367), murine acute kidney injury models (PMID: 40991986), and zebrafish/mouse cardiomyopathy models (PMID: 25504881).
Preparation & Dosage
Traditional preparation
No human dosages have been established. Animal studies used 2.5-10 mg/kg orally (in rats, solubilized in 25% Captisol®) or 30-60 mg/kg intraperitoneally. Aqueous extracts of A. visnaga showed enhanced bioavailability compared to pure visnagin. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Visnagin is a naturally occurring furochromone (furanochromone) compound, not a conventional food ingredient, so it lacks a traditional macronutrient or micronutrient profile. It is a pure bioactive small molecule (molecular formula: C11H10O4, molecular weight: 206.19 g/mol) isolated primarily from the seeds of Ammi visnaga (toothpick weed/khella plant). As a concentrated phytochemical compound, it does not contribute meaningful calories, proteins, fats, or carbohydrates in its isolated form. Key bioactive characteristics include: furochromone scaffold conferring antioxidant and anti-inflammatory activity; structural similarity to khellin, another Ammi visnaga-derived compound; demonstrated capacity to inhibit NLRP3 inflammasome activation relevant to its kidney-protective effects. Bioavailability notes: Being a lipophilic small molecule with moderate polarity, visnagin is expected to have reasonable oral bioavailability, though specific pharmacokinetic data in humans is limited; animal studies suggest hepatic metabolism via cytochrome P450 enzymes; the compound shows good tissue distribution including cardiac and renal tissues as evidenced by experimental models. No established dietary reference intakes or nutritional concentration benchmarks exist, as visnagin is studied as a pharmacological agent rather than a dietary nutrient. Research doses in animal models typically range from 5–50 mg/kg body weight.
How It Works
Mechanism of Action
Visnagin suppresses NF-κB-mediated inflammatory signaling, reducing downstream pro-inflammatory cytokines such as TNF-α and IL-6 that drive acute organ injury. In cardiac tissue, it has been shown to inhibit mitochondrial dysfunction pathways triggered by doxorubicin, preserving cardiomyocyte viability without interfering with reactive oxygen species generation required for chemotherapeutic tumor killing. Its antioxidant activity involves upregulation of Nrf2-dependent cytoprotective enzymes, including heme oxygenase-1 (HO-1) and superoxide dismutase (SOD).
Clinical Evidence
Current evidence for visnagin is entirely preclinical, derived from animal models including zebrafish and rodents. In acute kidney injury models, visnagin administration reduced serum creatinine and blood urea nitrogen levels alongside decreased renal tissue expression of inflammatory markers (PMID: 40991986). Cardioprotective studies in doxorubicin-treated zebrafish and mouse models demonstrated preserved cardiac function measured by ejection fraction without attenuating tumor cell cytotoxicity. No human clinical trials have been conducted, making it premature to assign therapeutic dosages or confirm efficacy in humans.
Safety & Interactions
No human safety data or established tolerable dose ranges exist for visnagin as an isolated supplement, as all studies to date are preclinical. Its parent plant, Ammi visnaga, contains khellin and other furochromones known to cause photosensitivity, hepatotoxicity at high doses, and gastrointestinal upset, so similar risks may apply to visnagin. Potential interactions with chemotherapy agents warrant caution, and individuals on cardiac or nephroprotective medications should avoid use without medical supervision. Visnagin should be avoided during pregnancy and lactation due to a complete absence of safety data in these populations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
4-methoxy-7-methyl-5H-furo[3,2-g]chromen-5-oneKhella extract compoundAmmi visnaga furanochromoneVisnaganKellin analogBenzofuran chromone derivative
Frequently Asked Questions
What is visnagin and where does it come from?
Visnagin is a naturally occurring furochromone compound isolated from the seeds and aerial parts of Ammi visnaga, a flowering plant native to the Mediterranean and Middle East historically used in traditional medicine. It belongs to the same chemical class as khellin and has attracted research interest for its organ-protective and anti-inflammatory properties observed in laboratory settings.
Can visnagin protect the kidneys?
In rodent models of acute kidney injury, visnagin reduced key damage biomarkers including serum creatinine and blood urea nitrogen while decreasing renal expression of TNF-α and IL-6 (PMID: 40991986). These findings suggest a nephroprotective mechanism tied to anti-inflammatory and antioxidant activity, though no human trials have confirmed this effect and clinical translation remains unestablished.
Does visnagin interfere with chemotherapy?
Preclinical studies in zebrafish and mouse models found that visnagin protected cardiac tissue from doxorubicin-induced cardiomyopathy without reducing the drug's ability to kill cancer cells. This selectivity is thought to arise because visnagin targets mitochondrial stress pathways in cardiomyocytes rather than the reactive oxygen species mechanism doxorubicin uses to damage tumor cells. These results are promising but require validation in human oncology trials before clinical use.
What is the recommended dosage for visnagin supplements?
No human-validated dosage for visnagin exists because clinical trials have not been conducted. All effective doses reported are from animal studies and cannot be directly extrapolated to human supplementation. Until pharmacokinetic and safety data are established in humans, no dosage recommendation can responsibly be made.
Is visnagin safe to take with heart or kidney medications?
There are no documented drug interaction studies for isolated visnagin in humans, but its pharmacological activity on cardiac and renal inflammatory pathways raises theoretical concerns about additive or antagonistic effects with ACE inhibitors, diuretics, or nephroprotective agents. The related compound khellin from the same plant has documented interactions affecting smooth muscle tone. Consultation with a healthcare provider is essential before combining visnagin with any prescription medication.
What does the current research say about visnagin's effectiveness?
Current evidence for visnagin is primarily from laboratory and animal studies, including models showing kidney protection and heart health benefits. While these preliminary findings are promising, human clinical trials remain limited, meaning more research is needed to confirm efficacy and establish therapeutic relevance in people. The quality of evidence is considered preliminary rather than conclusive at this stage.
Who should consider taking visnagin supplements and who should avoid it?
Visnagin may be of interest to individuals concerned with kidney health or those seeking cardiovascular support, though limited human evidence exists. People with existing kidney or heart conditions, pregnant or nursing women, and those taking medications should consult a healthcare provider before supplementing, as adequate safety data in these populations is not yet established.
How is visnagin absorbed and does food affect its bioavailability?
Visnagin is a lipophilic compound derived from plants like khella, but specific bioavailability data in humans is limited. While fat-soluble compounds are generally better absorbed with dietary fat, no published studies have specifically examined how food composition affects visnagin absorption or optimal timing relative to meals.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w visnagin curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
